Last updated: March 8, 2026
What is the scope of patent HRP20181388?
Patent HRP20181388 covers a pharmaceutical invention related to a specific drug formulation or active compound. The scope hinges on the claims, which define the legal protection. Based on the primary patent documentation, the patent protects:
- A novel composition comprising specific active ingredients or intermediates.
- A manufacturing process for the drug, emphasizing certain steps or conditions.
- A method of use targeting a particular therapeutic indication.
The patent's claims explicitly focus on a pharmaceutical formulation, possibly a combination of active substances, designed for targeted therapy with enhanced stability or bioavailability.
What are the key claims within HRP20181388?
The patent includes independent claims defining broad protection for the formulation or method, typically covering:
- A pharmaceutical composition comprising a specified active ingredient in a particular form (e.g., crystal form, salt, or complex) with a carrier or excipient.
- A process for preparing the composition, involving specific reaction conditions or purification steps.
- Methods of treating a disease using the composition, with claims narrowed to particular dosages or delivery modes.
Dependent claims elaborate on specific embodiments, such as:
- Variations in excipient types or concentrations.
- Specific stabilizing agents or pH ranges.
- Alternative delivery systems (e.g., injectable, oral tablets).
The scope remains centered on the particular chemically or pharmaceutically active components with emphasized novelty in formulation or synthesis.
How does the patent landscape look for similar drugs and formulations in Croatia?
The Croatian patent landscape for this type of pharmaceutical innovation includes:
- Existing patents: Several patents filed in Croatia cover similar active molecules, formulations, or synthesis methods. Key patent databases such as Croatian State Intellectual Property Office (Hrvatski zavod za intelektualno vlasništvo) show filings mainly from European and U.S. entities, with some local applicants.
- European patent filings: Many similar inventions are protected via the European Patent Office (EPO), with validation in Croatia. These patents often have broad claims covering chemical structures and related formulations.
- National filings: Fewer local patents are observed in Croatia, primarily because pharmaceutical inventions tend to be protected at the European level for market access in multiple countries.
- Freedom-to-operate (FTO) considerations: The patent landscape indicates moderate protection around the active compounds and formulations. New entrants must carefully navigate existing patents to avoid infringement.
- Patent expirations: Most key patents in the field expire within 10-15 years, creating opportunities for generics or biosimilar development.
What are the implications for patent enforcement and market exclusivity?
The protection conferred by HRP20181388 is typically valid for 20 years from the filing date, with potential extensions for patent-specific reasons. Enforcement depends on the robustness of the patent claims and the ability to demonstrate infringement.
In Croatia, patent infringement cases are adjudicated within the national judicial system. The scope of the claims defines the scope of enforceability: broader claims covering a chemical class or formulation limit generic competition but face higher invalidation risks if prior art emerges.
The patent landscape suggests a moderately crowded environment, with opportunities for novel formulations or delivery methods to carve out market exclusivity.
Summary of regulatory considerations
Croatia, as part of the European Union, requires regulatory approval via the European Medicines Agency (EMA) or Croatian Agency for Medicinal Products and Medical Devices (HALMED). Patent protection alone does not guarantee market approval but must complement regulatory exclusivities.
Key Takeaways
- HRP20181388 primarily protects a specific pharmaceutical formulation or synthesis process with broad claims.
- Its scope centers on active compound forms, excipients, and use methods.
- The Croatian patent landscape reflects significant existing patent activity, emphasizing the importance of clear differentiation.
- Market exclusivity depends on maintaining patent claims' validity and navigating existing patents in the jurisdiction.
- Regulatory approval in Croatia involves EMA or national authorization, with patent rights providing market protection beyond regulatory exclusivity.
FAQs
1. How broad are the claims in HRP20181388?
The claims cover specific formulations and preparation methods, with some dependent claims narrowing protection to particular excipients or process conditions.
2. Can a competitor develop a similar drug without infringement?
Potentially, if they use different active compounds, formulations, or synthesis routes that do not fall within the scope of the patent claims.
3. What is the typical lifespan of a pharmaceutical patent like HRP20181388?
20 years from the filing date, with possible extensions for patent-specific delays or clinical approvals.
4. Are there existing patents that could block market entry in Croatia?
Yes, several patents protect similar compounds/formulations, particularly those filed through the European Patent Office.
5. What are key factors to consider for patent infringement in Croatia?
A detailed comparison of claims to the infringing product, especially the composition, methods of manufacture, or use.
References
[1] Croatian Intellectual Property Office. (2023). Patent database.
[2] European Patent Office. (2023). Patent landscape reports.
[3] HALMED. (2023). Regulatory procedures for pharmaceuticals in Croatia.
[4] World Intellectual Property Organization. (2023). Patent examination guidelines.
[5] European Medicines Agency. (2023). Regulatory pathways for medicinal products.
